A Study of LY3437943 in Chinese Participants With Obesity Or Overweight

Lilly

Status and phase

Completed

Phase 1

Conditions

Overweight

Obesity

Treatments

Drug: LY3437943

Drug: Placebo

Study type

Interventional

Funder types

Industry

Identifiers

NCT05548231

J1I-MC-GZBE (Other Identifier)

17954

Details and patient eligibility

About

The main purpose of this study is to learn about the safety and tolerability of LY3437943 when given to Chinese participants with overweight body mass index (BMI) or obesity. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. Each enrolled participant will receive injections of LY3437943 or placebo given just under the skin. For each participant, the study will last about 20 weeks excluding screening period and may include up to 20 visits to the study center.

Enrollment

32 patients

Sex

All

Ages

20 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

For All Participants:

Are native Chinese males or females
Have a body mass index of ≥27 and ≤40 kilograms per square meter (kg/m²)
Have not modified diet or adopted any nutritional lifestyle modification for 3 months
Have stable body weight for the last three months
Male participants must agree to use contraception during the study and for 4 months afterward and female participants must be woman of nonchildbearing potential

For Type 2 Diabetes Mellitus (T2DM) Participants:

Have type 2 diabetes for at least 3 months
Have a glycated hemoglobin (HbA1c) value of ≥7.0% and ≤10.5% and have been treated with diet and exercise alone or a stable dose of metformin for at least 3 months prior to screening

Exclusion criteria

For All Participants:

Have an average weekly alcohol intake that exceeds 21 units per week (males) and 14 units per week and smoke more than 10 cigarettes, or cigarette equivalent (as determined by investigator), per day
Have other serious or unstable illnesses
Have had an episode of severe hypoglycemia
Current or chronic history of liver disease.

For T2DM Participants:

Have type 1 diabetes mellitus
Have uncontrolled diabetes, defined as an episode of ketoacidosis or hyperosmolar state requiring hospitalization
Any glucose-lowering medications other than metformin within 3 months prior to screening